University of Birmingham Endowment

ChromaTwist is a developer of innovative ultraviolet fluorescent dyes designed for applications in bio-sensing and bio-imaging diagnostic tests. The company's proprietary technology platform utilizes shifted organic fluorescent dyes, which emit visible light upon UV irradiation. These dyes are composed of aromatic organic materials featuring donor and acceptor groups, allowing them to absorb UV light and emit across the full visible spectrum. ChromaTwist's modular and scalable chemistry enables the continuous advancement of their fluorophores, thereby expanding their potential applications in the healthcare sector, particularly in areas like flow cytometry and multiphoton microscopy.

ChromaTwist is a developer of innovative ultraviolet fluorescent dyes designed for applications in bio-sensing and bio-imaging diagnostic tests. The company's proprietary technology platform utilizes shifted organic fluorescent dyes, which emit visible light upon UV irradiation. These dyes are composed of aromatic organic materials featuring donor and acceptor groups, allowing them to absorb UV light and emit across the full visible spectrum. ChromaTwist's modular and scalable chemistry enables the continuous advancement of their fluorophores, thereby expanding their potential applications in the healthcare sector, particularly in areas like flow cytometry and multiphoton microscopy.

Linear Diagnostics Limited is a diagnostic technology company based in Birmingham, United Kingdom, founded in 2011. The company specializes in developing a novel diagnostic platform that utilizes linear dichroism (LD) to perform a wide range of molecular diagnostics tests. This technology allows for the rapid detection of multiple targets from a single sample, providing significant advantages over conventional methods. Linear Diagnostics focuses on various applications, including the detection of antibiotic resistance in infections and identifying bacteria responsible for food crop spoilage. Additionally, the company offers a handheld reader designed for measuring LD signals, enhancing the accessibility and efficiency of its diagnostic solutions. By addressing limitations associated with traditional detection techniques, Linear Diagnostics aims to improve healthcare outcomes and reduce costs.

Tyseley Energy Park develops an Energy Innovation Zone (EIZ) to help Tyseley and Birmingham overcome the severe energy business and social challenges it currently faces. The TEP EIZ reduces emissions and stimulates growth and will integrate low carbon technologies and infrastructure needed to support new approaches to clean energy.

Smart Antenna Technologies (SAT) is a spinout company from the University of Birmingham. The team have designed, developed and patented a pioneering smart antenna technology. The market for this highly scalable technology is the global cellular handset market. SAT's remarkable innovation has led to the creation of a significant number of patent applications, both filed and in process. Today, handset manufacturers are seeking an effective antenna solution suitable for implementing the next generation of cellular handset technologies, known as Long Term Evolution (4G LTE). Currently, they are unable to achieve physically the desired antenna performance in a size that fits a cellular handset package at an acceptable volume cost. Current implementations from the leading handset manufacturers employ typically six antennas. The highly compact SAT technology replaces all existing antennas—DVB-H, Bluetooth, Wi-Fi, GSM, GPS, 3G multi-bands and 3.9/4G LTE—with just one. This single SAT device provides significantly lower costs, is smaller in size and offers much needed performance gains over existing designs and technology.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.